Skip to content
Get the Balanced News app for a better experience!
The Balanced News Logo
Analytics
The Balanced News Logo

Stay Balanced, Stay Informed

Menu
  • Browse News
  • Underreported Stories
  • Curated Feeds
  • Insights
  • Analytics
  • Our Writers
  • About Us
  • Download App
Learn
  • How It Works
  • Bias Detection
  • Lens Score
  • Source Bias Checker
  • Accountability
  • Custom Feeds
Newsroom
  • Writers & Analysts
  • About TBN
  • Editorial Standards
  • Corrections Policy
  • Our Partners
  • Insights
Socials
  • Youtube
  • Instagram
  • X
  • Facebook
News Categories
  • Trending
  • Politics
  • Sports
  • Business
  • Tech
  • Entertainment
  • Health
  • Science
  • Crime
  • Lifestyle
  • National
  • International
  • Good News
  • Crypto

Get Our App

Available for iOS and Android


LensFeedsInsightsAnalyticsTrendingGood NewsSportsPoliticsBusinessCrimeTechEntertainmentHealthNationalInternational

© 2026 The Balanced News. All rights reserved.

About UsEditorial StandardsCorrectionsHelp & SupportPrivacy PolicyTerms & Conditions
Molbio Diagnostics Sets IPO Price Band at Rs 768-807, Subscription Opens August 10

Categories

Categories

Related Coverage

Select a news story to see related coverage from other media outlets.

Related Coverage

Select a news story to see related coverage from other media outlets.

  1. Home
  2. /
  3. Business

Molbio Diagnostics Sets IPO Price Band at Rs 768-807, Subscription Opens August 10

Analysed 5 Aug 2026·2 sources analysed·Goa, India·Business
Molbio Diagnostics Sets IPO Price Band at Rs 768-807, Subscription Opens August 10PreviousNext

Molbio Diagnostics Limited has set its IPO price band between Rs 768 and Rs 807 per share, with subscription opening on August 10 and closing on August 12. Anchor investor allocations will occur on August 7. The IPO includes a fresh issue worth up to Rs 200 crore and an Offer For Sale by existing shareholders. Proceeds will fund infrastructure, equipment, and general corporate purposes. The company expects a post-issue valuation of around Rs 9,300 crore, with shares reserved for institutional and retail investors.

Sentiment
51%
TBN's observations

First-hand measurement across 2 sources

We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (51/100). Lens Score 44/100.

Outlets measured: news18, mint. See how each one headlined and framed the same story in the source comparison below.

AI analysis of 2 sources · Published under editorial oversight by The Balanced News
Analysed 5 Aug 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Sentiment — Neutral (51/100)

Sentiment was consistent across outlets (50–52/100), indicating broadly factual reporting rather than editorialising.

Coverage timeline

mint broke this story on 5 Aug, 03:26 am. Other outlets followed.

5 Aug, 03:26 am2 sources · 66 min5 Aug, 04:32 am
AI analysis by the TBN Bias Engine · beat methodology byMrunal Wange· Business & Economy Editor· editorial standards byOjas Kale
← Previous
India Advances Quality Regulations with QCOs and Digital Smart Standards Launch
Next →
AI Startup Founder Apologizes After Offering Job Interviews for Tattoos at Event
1
mint5 Aug, 03:26 am
Molbio Diagnostics IPO: Price band set at 768-807 per share; check key dates, issue details Stock Market News
  • 2
    news185 Aug, 04:32 am
    Molbio Diagnostics sets IPO price band at Rs 768-807; issue to open on Aug 10
  • Who's involved

    Institutions and figures named across source coverage.

    Corporate
    Motilal Oswal Investment AdvisorsIIFL Capital ServicesMotilal Oswal Private EquityJefferies IndiaIndia Business Excellence Fund IIIKotak Mahindra Capital CompanyMolbio Diagnostics LimitedExxora Trading Limited Liability PartnershipTemasek

    Story context

    Category
    Business
    Location
    Goa, India
    Sources analysed
    2
    Last analysed
    5 Aug 2026
    Key entities
    Initial public offeringIndian rupeeEquity (finance)CroreDiagnosisShareholderTemasek HoldingsPrivate equityGoaNew DelhiGuru DuttCapital expenditure